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ABSTRACT
Gastric cancer (GC) has high mortality owing to its aggressive nature. Tumor angiogenesis 
plays an essential role in the growth, invasion, and metastatic spread of GC. The aim of this 
work was to review the angiogenic biomarkers related to the behavior of GC, documented 
in the literature. A search of the PubMed database was conducted with the MeSH terms: 
“Stomach neoplasms/blood [MeSH] or stomach neoplasms/blood supply [MeSH] and 
angiogenic proteins/blood [Major]”. A total of 30 articles were initially collected, and 4 were 
subsequently excluded. Among the 26 articles collected, 16 examined the role of vascular 
endothelial growth factor (VEGF), 4 studied endostatin, 3 investigated angiopoietin (Ang)-
2, 2 studied the Ang-like protein 2 (ANGTPL2), and 1 each examined interleukin (IL)-12, 
IL-8, and hypoxia inducible factor. Regarding VEGF, 6 articles concluded that the protein 
was related to lymph node metastasis or distant metastases. Five articles concluded that 
VEGF levels were elevated in the presence of GC and decreased following tumor regression, 
suggesting that VEGF levels could be a predictor of recurrence. Four articles concluded that 
high VEGF levels were correlated with poor prognosis and lower survival rates. Ang-2 and 
ANGTPL2 were elevated in GC and associated with more aggressive disease. Endostatin was 
associated with intestinal GC. VEGF is the most extensively studied angiogenic factor. It is 
associated with the presence of neoplastic disease and lymph node metastasis. It appears to 
be a good biomarker for disease progression and remission, but not for diagnosis. The data 
regarding other biomarkers are inconclusive.
Keywords: Angiogenic proteins; Stomach neoplasms; Lymph nodes; Neoplasm metastasis; 
Vascular endothelial growth factor A; Recurrence
INTRODUCTION
Gastric cancer (GC) is the fourth most common cancer, responsible for more than 800,000 
deaths worldwide each year. Despite the decline in mortality rates observed in recent 
decades, GC remains second only to lung cancer as a cause of cancer-related deaths. More 
than one million people are newly diagnosed with GC each year, imposing a heavy burden on 
world health services [1].
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Gastric Cancer and Angiogenesis: Is 
VEGF a Useful Biomarker to Assess 
Progression and Remission?
The 5-year survival rates are 50% in patients with advanced cancer and 95% in patients who 
are diagnosed early [1]. The high mortality rate is related to the late diagnosis owing to non-
specific manifestations of the disease in the early phases, as well as to its aggressive nature, 
which is associated with mutations of various genes and abnormalities in several growth 
factors and their receptors [2].
Tumor angiogenesis and lymphangiogenesis play an essential role in the growth, invasion, 
and metastatic spread of solid neoplasms by facilitating the delivery of oxygen, nutrients, 
and growth factors to tumor cells. Angiogenesis is regulated by certain essential molecules. 
Vascular endothelial growth factor (VEGF) is one of the most important factors driving 
tumor angiogenesis. The VEGF family consists of 7 members: VEGF-A, VEGF-B, VEGF-C, 
VEGF-D, VEGF-E, VEGF-F, and placental growth factor (PlGF). These proteins act through 
specific tyrosine kinase receptors (VEGF receptor 1 [VEGFR1], VEGFR2, and VEGFR3), 
expressed primarily on endothelial cells. Most of these molecules are transported by platelets 
and released into serum after platelet degranulation during blood clotting; only a small 
proportion circulate freely in the bloodstream [3].
In 1971, Folkman [4] established the importance of angiogenesis in tumorigenesis. He 
suggested that tumor growth and expansion are closely related to the development of a 
network of blood vessels within a tumor. Thus, the blocking of angiogenesis can be a good 
strategy to prevent tumor growth.
Endostatin is an endogenous tumor angiogenesis inhibitor. It inhibits tumor angiogenesis and 
metastasis by limiting tumor blood supply, thereby depriving tumors of nutrients, and has been 
considered as a potential anticancer marker in the treatment of malignant tumors [5].
Angiopoietins (Ang) are thought to be important factors in vascular maturation and 
stability during angiogenesis [6]. Of the 4 Ang proteins identified (Ang-1 to Ang-4), the 
best characterized are Ang-1 and Ang-2. They are both ligands of Tie-2, a receptor expressed 
on endothelial cells, and they play critical roles in angiogenesis. Binding of Ang-1 to Tie-2 
maintains and stabilizes mature vessels by promoting interactions between endothelial cells 
and the surrounding extracellular matrix. Ang-2 shows context-dependent, proangiogenic, 
and antiangiogenic activities [7].
In recent years, a significant focus on the identification of biomarkers for early detection 
of GC has been observed. In the present report, the authors performed a literature review 
regarding the role of angiogenic biomarkers in GC.
SEARCH METHODS
A PubMed search was conducted focusing on angiogenesis in GC. The MeSH database was 
searched with the terms: “Stomach neoplasms/blood [MeSH] or stomach neoplasms/blood 
supply [MesH] and angiogenic proteins/blood [Major]”.
A total of 30 articles were initially collected. Four articles were subsequently excluded 
from this review: one was excluded because the subject of the study was neuroendocrine 
carcinomas, and no GCs were examined; another paper was excluded because it was a letter 
to the editor; another because the article was written in Romanian; and another was excluded 
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because it evaluated the most suitable compartment for the assessment of VEGF, and thus it 
did not study the molecule itself. Ultimately, 26 studies were included in the analysis.
TUMOR MARKERS
The main results of the selected studies are listed in Table 1. Conventional tumor markers 
do not allow diagnosis of GC with adequate sensitivity and specificity; their use is limited 
to prognosis and follow-up recommendations [8]. However, several studies presently 
underway are attempting to establish new molecules as tumor markers [9]. Currently, 
preoperative staging relies on imaging studies, but these modalities cannot confirm 
or exclude the presence of metastatic lymph nodes. This is a very important issue in 
determining the ideal treatment for an individual, such as the choice of gastrectomy vs. 
submucosal resection [10,11].
VEGF FAMILY
In the study of Wang et al. [10], the level of VEGF-C in serum was demonstrated to be higher 
in patients with lymph node metastasis (P<0.001) and with distant metastasis (P<0.001). 
VEGF-C and VEGF-D are both ligands for VEGFR-3 on the surface of lymphatic endothelial 
cells and act as regulators of lymphangiogenesis; these had been reported to be important 
factors in stimulating lymphangiogenesis and lymphatic metastasis [12]. Similarly, Tsirlis 
et al. [11] verified that in the preoperative period, VEGF-C levels were lower and VEGF-D 
levels were higher in patients with cancer when compared with controls (P<0.001). In the 
postoperative period, VEGF-C levels increased and VEGF-D levels decreased compared 
with the preoperative level (P<0.001). Serum VEGF-C and VEGF-D levels were identified as 
statistically significant independent predictors of the presence of GC (P<0.001). The VEGF-C/
VEGF-D ratio was found to be the most potent predictor of malignancy (P<0.001). Wang et 
al. [13] found that the serum VEGF-C level was significantly higher in patients with GC than 
in controls (P<0.001). VEGF-C positive expression was higher in GC tissue (P=0.001) and 
in areas of higher lymph vessel density (P<0.001). There was a positive correlation between 
serum VEGF-C and lymph node metastasis (P<0.001). The group of patients with VEGF-C 
positive expression had a shorter mean survival time. High expression of VEGF-C may be 
used as a biomarker for the development of GC and may predict unfavorable survival rates. 
It appears that VEGF-C produced by cancer cells may increase the expression of VEGFR-3 on 
lymphatic endothelial cells and promote the formation of new lymphatic vessels [13].
As part of a search for angiogenic activators and their receptors, Kikuchi et al. [14] concluded 
that VEGF levels were higher in patients than in controls, but interestingly, VEGFR-1 and 
VEGFR-2 levels were lower. VEGF showed the greatest sensitivity and specificity as a marker 
associated with intestinal-type cancer, while VEGFR-1 showed the highest sensitivity and 
specificity for early GC and VEGFR-2 showed the greatest sensitivity and specificity for 
diffuse-type and advanced cancer.
VEGF is stored in alpha granules and released upon platelet activation during clotting, while 
peripheral blood cells such as platelets, granulocytes, and lymphocytes also express VEGF 
[15]. Accordingly, some researchers have used VEGF per platelet count to correct for the 
variation of serum VEGF levels in cancer patients with different platelet counts. Seo et al. 
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[16] compared advanced GC with early cancer. Serum VEGF levels were higher in advanced 
cancer, and a positive correlation was observed between serum VEGF and platelet counts 
in these patients (P<0.001). Overall survival (OS) (P=0.040) and progression-free survival 
(P=0.010) were shorter in patients with high serum VEGF per platelet count.
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Table 1. Main results of selected studies
Study/author Year No. Molecule Conclusion Values
Wang et al. [10] 2012 80 patients 
0 controls
VEGF-C Preoperative diagnosis of lymph node 
metastasis and distant metastasis (P<0.001).
- Cut-off value of 542.5 pg/mL.
- Sensitivity of 82.5%, specificity of 92.3%.
Tsirlis et al. [11] 2010 40 patients 
40 controls
VEGF-C and 
VEGF-D
Detection and staging in GC (P<0.001). -  VEGF-C cut-off value 1.1 pg/mL, sensitivity 83%, 
specificity 70%.
-  VEGF-D cut-off value 370 pg/mL, sensitivity 
88%, specificity 73%.
-  VEGF-C/D ratio cut-off value 2.7, sensitivity 88%, 
specificity 75%.
Kikuchi et al. [14] 2011 164 patients 
164 controls
VEGF, VEGFR-1, 
and VEGFR-2
VEGF level is elevated in patients with GC, 
VEGFR-1, and VEGFR-2 are reduced compared 
to controls.
-  VEGF cut-off value of 415 pg/mL, sensitivity of 
63.5%, and specificity of 65.1%, for intestinal 
type cancer.
-  VEGFR-1 cut-off value of 46 pg/mL, sensitivity of 
60%, and specificity of 58.6%, for early cancer.
-  VEGFR-2 cut-off value of 8,314 pg/mL, sensitivity 
of 66.3%, and specificity of 61.6%, for advanced 
and diffuse type cancer.
2010 181 patients 
113 controls
VEGF Poor OS and progression-free survival in 
advanced GC.
Sheng et al. [17] 2008 92 patients 
92 controls
VEGF It was higher in GC patients than in healthy 
controls and benign gastric disease.
-  VEGF cut-off value of 217.79 pg/mL, sensitivity of 
40.2%, and specificity of 93.7%, by TR-IFMA.
Association with distant metastases, invasion 
depth of the tumor and tumor stage.
Wang et al. [13] 2007 80 patients 
20 controls
VEGF-C Lymph node metastasis and poor prognosis. -  Serum VEGF-C cut-off value of 367.5 ng/L, 
sensitivity of 85%, and specificity of 80%, for 
GC diagnosis.
-  Serum VEGF-C cut-off value of 542.5 ng/L, 
sensitivity of 82.8%, and specificity of 81.8%, for 
lymph nodes metastasis diagnosis.
Ding et al. [18] 2005 135 patients 
48 controls
VEGF-A Levels were higher in patients with GC 
(P<0.010) and they decreased following 
tumor excision (P<0.001).
Park et al. [19] 2015 381 patients  
(118 Caucasians 
+263 Asians) 
0 controls
VEGF-A and 
VEGFR-2/CD31
Caucasians had a median VEGF-A level 
that was 95% higher than that of Asians 
(P<0.001).
Survival was worse in Caucasians with high 
VEGFR-2/CD31 levels (P=0.038).
These were independent predictors of 
survival only in Caucasians.
Villarejo-Campos 
et al. [3]
2013 59 patients 
0 controls
VEGF Levels decreased after treatment (P<0.010). 
Preoperative levels were independent 
prognostic factor.
-  Preoperative VEGF values over 761 pg/mL were 
associated with shorter patient survival.
Vidal et al. [20] 2009 97 patients 
20 controls
VEGF Higher in patients with GC than controls 
(P=0.002).
-  Serum VEGF over 320 pg/mL was the only 
preoperative predictor of both recurrence and 
disease-specific survival.
Bilgiç et al. [21] 2015 30 patients 
30 controls
VEGF Correlation with the tumor type classification 
and the presence of distant tissue invasion.
Konno et al. [33] 2003 37 patients 
10 controls
VEGF Higher in patients with GC than controls and 
higher in patients with venous invasion.
Blank et al. [34] 2015 76 patients 
0 controls
VEGF Prognostic relevance in patients with primary 
resection (P=0.028).
Park et al. [35] 2014 147 patients 
0 controls
VEGF-A Higher in patients with R1 vs. R0 resection 
(P=0.037).
Significant independent prognostic factor for 
survival (P=0.028).
VEGF = vascular endothelial growth factor; VEGFR = vascular endothelial growth factor receptor; GC = gastric cancer; OS = overall survival; TR-IFMA = time-
resolved immunofluorometric assay; CD31 = cluster of differentiation 31; R1 = circumferential resection with margin involvement; R0 = circumferential resection 
without margin involvement.
Sheng et al. [17] used a time-resolved immunofluorometric assay (TR-IFMA) to 
measure VEGF levels in blood, instead of a radioimmunoassay (RIA) or enzyme-linked 
immunosorbent assay (ELISA). Compared with these techniques, TR-IFMA is characterized 
by lower detection limits and greater specificity, reproducibility, and practicability. Plasma 
VEGF levels in patients with benign stomach disease were higher than in controls (P=0.040) 
but lower than the levels in patients with GC (P=0.030). Higher VEGF levels were detected 
as the disease stage and the invasion depth of the tumor increased P=0.030 and P=0.040, 
respectively, and in patients with distant metastases P=0.009. There was no significant 
association between VEGF levels and the presence of lymph node metastasis [17].
Ding et al. [18] reported that VEGF-A levels were significantly higher in both serum and 
plasma from patients with GC (P<0.010). Surgical excision of tumors resulted in a significant 
reduction of VEGF-A levels, suggesting that VEGF-A was secreted by the tumor mass.
Park et al. [19] compared gastric carcinoma characteristics and the expression of VEGF-A 
between Caucasian and Asian patients. Caucasian patients had more proximal tumors, a 
higher incidence of vascular invasion, a higher incidence of neural invasion, and a more 
advanced tumor, node and metastasis (TNM) stage. The median level of serum VEGF-A 
in Caucasian patients was nearly twice that observed in Asian patients, and this value 
was associated with significantly poorer survival (P<0.001). Serum VEGF-A level was an 
independent prognostic factor for survival in Caucasian patients but it did not demonstrate 
prognostic value in Asian patients. Patients with higher VEGFR-2/cluster of differentiation 31 
(CD31) levels had significantly worse survival rates. Villarejo-Campos et al. [3] found similar 
results, and demonstrated that serum VEGF levels decreased after treatment in patients 
with high-grade cancers (P=0.010), locally advanced cancers (P=0.030), large number of 
positive regional lymph nodes (P=0.040), and resectable tumors (P<0.010). Preoperative high 
serum VEGF levels >761 pg/mL were associated with shorter patient survival. Preoperative 
serum VEGF and the number of involved lymph nodes were independent prognostic factors. 
Preoperative serum VEGF-C values showed conflicting results.
Vidal et al. [20] evaluated the preoperative serum VEGF and urokinase-type plasminogen 
activator (uPA) levels in patients undergoing GC resection. Serum levels of VEGF in patients 
with GC were significantly higher than in controls (P=0.002). Higher preoperative serum 
VEGF levels were associated with advanced disease (advanced TNM stage, perineural 
invasion, and high lymph node ratio), a lower probability of recurrence-free status (P=0.033), 
and shorter disease-specific survival (P=0.004). No significant findings were observed in 
relation to serum uPA as a prognostic factor.
Other studies corroborated the value of VEGF-A as a GC biomarker. For example, Bilgiç et 
al. [21] found that serum levels of VEGF were correlated with tumor type classification and 
the presence of distant tissue invasion, and Ilhan et al. [22] demonstrated a statistically 
significant increase in VEGF levels directly proportional to the cancer stage (P<0.001). 
Significantly higher VEGF levels were found in patients with cancer than in healthy 
controls, and the increased VEGF levels were not related to infection (P>0.050). Levels of 
malondialdehyde, a reactive compound that occurs naturally in situations of oxidative stress, 
were higher both in patients with GC compared with healthy controls and in patients with 
cancer and infection compared with those with cancer without infection (P<0.001). Levels 
were also significantly elevated in cases of metastasis and invasion of other tissues (P<0.001).
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ANG/ENDOSTATIN FAMILY
Procalcitonin and C-reactive protein levels were significantly higher in patients with cancer 
and infection than in patients with GC without infection, and were significantly higher in all 
GC groups than in the control group (P<0.001) [22]. Masiak et al. [23] observed a correlation 
between the histological differentiation and serum concentrations of endostatin (higher 
grades demonstrated higher concentrations of endostatin). However, the same was not 
true for epidermal growth factor (EGF) serum concentrations. The difference between the 
concentrations of endothelial growth factor (EGF) and endostatins in controls and patients 
were not statistically significant.
Ang are ligands of the endothelial cell surface receptor Tie-2. They inhibit Tie-2 and act as 
negative regulators of angiogenesis [7]. Wang et al. [24] performed a review of studies of 
endostatin. The meta-analysis showed an increased level of endostatin in patients with GC 
(P<0.001), a lower serum endostatin level in lower grade tumors (P<0.001), and a higher 
serum endostatin level in lymph node invasion (P<0.001). These results suggest that serum 
endostatin levels might be related to the aggressiveness of GC, could contribute to lymph 
node metastasis, and could be an important prognostic biomarker in predicting the survival 
of patients with metastatic GC.
Koç et al. [25] suggested that serum levels of endostatin were correlated with the histologic 
classification of gastric tumors because higher endostatin levels were observed in intestinal 
type than in diffuse type tumors. Additionally, Woo et al. [26] concluded that pretherapeutic 
serum endostatin (P<0.001) and VEGF (P<0.001) levels were higher in patients with GC. The 
serum endostatin (P<0.001) and VEGF (P=0.001) levels were significantly higher in patients 
with metastasis than in patients without distant metastasis. The levels of endostatin (P<0.001) 
and VEGF (P=0.002) were significantly correlated with the presence of distant metastases. The 
most significant prognostic factor for survival was the disease stage, but patients with a serum 
endostatin level >79.2 ng/mL had a relative risk of dying of 2.4 (P=0.013).
On the other hand, Engin et al. [27] found that concentrations of Ang-2 and Tie-2 were 
significantly higher in patients with GC than in controls, while concentrations of Ang-1 were 
not statistically different between the groups. Concentrations of Ang-1, Ang-2, and Tie-2 were 
not statistically different among the cancer stages. Jo et al. [28] reported that serum Ang-2 
levels were higher in patients than in controls, and that the levels were strongly correlated 
with the presence of positive lymph nodes (P=0.008). Elevated Ang-2 levels and depth of 
tumor invasion were significant predictors of lymph node metastasis.
ANG-LIKE FAMILY
Yoshinaga et al. [29] studied Ang-like protein 2 (ANGPTL2), a protein that regulates 
angiogenesis, and reported that the expression and production of ANGPTL2 were both 
higher in undifferentiated cells (P<0.001 and P<0.050, respectively). Levels of ANGPTL2 
in the serum of patients with GC were higher than those in healthy controls (P<0.010). 
Regarding angiogenic factors that were potential biomarkers for GC, only VEGF expression 
was confirmed in undifferentiated and differentiated cell lines. For the discrimination of 
patients with GC from individuals without cancer, the area under the curve for ANGPTL2 was 
0.774 (P=0.005). Toiyama et al. [30] concluded that serum ANGPTL2 was significantly higher 
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in patients with GC (P<0.050) and that its expression was associated with tumor progression, 
early recurrence (P=0.003), and poor prognosis (P=0.007).
INTERLEUKIN (IL) FAMILY
IL-12 is a cytokine produced by antigen-presenting cells with potent anti-tumor, anti-
angiogenic, and anti-metastatic activities. IL-12 induces type 1 immune response and acts 
as a growth factor for T cells. VEGF inhibits the maturation of dendritic cells, which are the 
main source of IL-12 [31]. Nakayama et al. [32] concluded that IL-12-positive cell density 
significantly decreased in patients with carcinoembryonic antigen (CEA)-positive (P=0.037) 
or differentiated type (P=0.036) tumors. IL-12-positive cell density was not associated with 
serum levels, but tended to be inversely correlated with plasma levels of VEGF (P=0.080). 
Patients with GC with low IL-12-positive cell density or low serum levels of IL-12 might 
require additional immunochemotherapy after surgery [32].
Konno et al. [33] investigated IL-8, a cytokine with mitogenic activity. Plasma VEGF 
levels were higher in patients with GC, and even higher in patients with venous invasion. 
Peripheral levels of VEGF were correlated with the number (P=0.0064) and ratio (P=0.0058) 
of metastatic lymph nodes. IL-8 levels in drainage veins were related to both tumor site and 
lymph node metastases. Shorter disease-free survival was found to be associated with high 
IL-8 levels (>3.65 ng/mL), large tumors (>40 mm), deeply invasive tumors, lymph node 
involvement, and venous invasion.
STUDIES THAT COVER MULTIPLE FAMILIES
Blank et al. [34] studied several proteins. Lower VEGF and follistatin levels in serum were 
correlated with distant metastases (P=0.040 and P=0.002, respectively). Lower follistatin 
levels were also correlated with lymph node metastasis (P=0.031). Lower serum Ang-2 levels 
were correlated with lymph node metastasis (P=0.025). Higher serum VEGF levels were 
associated with positive lymph nodes (P=0.025). The VEGF levels (P=0.011) and the Ang-2/
VEGF ratio (P=0.009) in the tissue were correlated with the extent of tumor regression. The 
Ang-2/VEGF ratio was also associated with clinical response (P=0.029), with a higher ratio in 
patients showing a positive response.
Park et al. [35] also studied a plethora of proteins, and showed higher VEGF-A levels in 
patients undergoing R1 resection compared with those undergoing R0 resection (P=0.037). 
Higher EGF levels were found in patients with poorly differentiated or undifferentiated 
tumors (P=0.020). Higher fibroblast growth factor 2 (FGF2) levels were observed in diffuse-
type and undifferentiated tumors, as well as in extensive nodal disease (P=0.017, P=0.042, 
and P=0.046, respectively). OS was significantly worse in patients with higher levels of 
VEGF-A, hepatocyte growth factor (HGF), EGF, or FGF2. The VEGF-A level was a statistically 
significant independent prognostic factor for OS.
Gao et al. [36] documented that levels of CEA, cancer antigen (CA)-50, CA 19-9, laminin, and 
collagen type IV can be used as a parameter for metastasis and disease progression because 
their levels were significantly higher in patients with metastasis (P<0.050).
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HYPOXIA-INDUCIBLE FACTOR (HIF) FAMILY
HIF-1α is a critical transcription factor that activates the transcription of VEGF under hypoxic 
conditions and promotes tumor cell survival [37]. Hypoxia can also induce p53 that lacks 
its function and shows diminished apoptotic potential [38]. Oh et al. [39] demonstrated 
that p53 and HIF-1α were positively correlated with invasion depth (P=0.015 and P=0.001, 
respectively), and p53 and VEGF levels were correlated with lymph node involvement 
(P=0.040 and P=0.010, respectively). HIF-1α was observed to be a poor prognostic factor for 
disease recurrence or progression (P=0.002).
CONCLUSIONS
High levels of angiogenic and growth factors in serum and tumors are associated with 
worse outcomes in patients with gastric carcinomas. VEGF-A, the most extensively studied 
angiogenic factor, appears to be a useful biomarker for disease progression and remission, 
but not for diagnosis.
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